NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $11.04 -0.22 (-1.95%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.04 0.00 (0.00%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nurix Therapeutics Stock (NASDAQ:NRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$10.86▼$11.3250-Day Range$9.72▼$13.1852-Week Range$8.18▼$29.56Volume533,693 shsAverage Volume999,154 shsMarket Capitalization$844.01 millionP/E RatioN/ADividend YieldN/APrice Target$28.87Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreNRIX MarketRank™: Nurix Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 517th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.25% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.25% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.72 News SentimentNurix Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.Search Interest11 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $233,238.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Stock News HeadlinesHoute Hans Van Sells 4,304 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) StockJuly 31 at 7:00 AM | insidertrades.com6NRIX : 6 Analysts Assess Nurix Therapeutics: What You Need To KnowJuly 31 at 5:51 PM | benzinga.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%. | Altimetry (Ad)Nurix Therapeutics price target lowered to $34 from $36 at H.C. WainwrightJuly 15, 2025 | finance.yahoo.comNurix Therapeutics Could Disrupt BTK Therapy And Reward InvestorsJuly 13, 2025 | seekingalpha.comNurix Therapeutics beats quarterly expectations on strong collaboration ...July 11, 2025 | investing.comNurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateJuly 10, 2025 | finanznachrichten.deNurix Therapeutics Reports Increased Revenue Amid Net LossJuly 9, 2025 | tipranks.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.84 on January 1st, 2025. Since then, NRIX shares have decreased by 41.4% and is now trading at $11.04. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings results on Wednesday, July, 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.27. The company earned $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative trailing twelve-month return on equity of 45.26%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional investors of Nurix Therapeutics include ARK Investment Management LLC (2.06%), Sumitomo Mitsui Trust Group Inc. (1.82%), AlphaQuest LLC (0.06%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.03%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V). Company Calendar Last Earnings7/09/2025Today8/01/2025Next Earnings (Estimated)10/10/2025Fiscal Year End11/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Price Target for Nurix Therapeutics$28.87 High Price Target$41.00 Low Price Target$16.00 Potential Upside/Downside+161.5%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($2.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$193.57 million Net Margins-234.57% Pretax Margin-233.61% Return on Equity-45.26% Return on Assets-34.71% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio6.82 Sales & Book Value Annual Sales$88.38 million Price / Sales9.55 Cash FlowN/A Price / Cash FlowN/A Book Value$5.85 per share Price / Book1.89Miscellaneous Outstanding Shares76,449,000Free Float70,792,000Market Cap$844.00 million OptionableOptionable Beta2.15 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:NRIX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.